Spyre Therapeutics Reports Q3 Operating Loss
Q3 income from operations was below the IBES estimate.
Story updates
09:04:24 PM UTC
SquawkNews
SPYRE THERAPEUTICS INC Q3 OPERATING EXPENSES USD 105.719 MILLION
Related stories
Innospec Reports Third-Quarter Revenue of $473.6 Million
M impact | EQUITY | Nov 03, 2026, 09:54 PM UTC
trivago Q3 2026 revenue rises 16% to €192.50 million
M impact | EQUITY | Nov 03, 2026, 09:46 PM UTC
Block raises full-year gross profit outlook; shares rise after hours
Block raised its full-year gross profit outlook, and its shares rose in after-hours trading.
M impact | EQUITY | Nov 03, 2026, 09:45 PM UTC
Talos Energy Borrowing Base Rises to $850 Million After Acquisition
Talos Energy's borrowing base increased to $850 million in conjunction with its completed Gulf of America bolt-on acquisition.
L impact | EQUITY | Nov 03, 2026, 09:45 PM UTC
Astera Labs’ Q3 Profit Rises to $182.944 Million
Astera Labs reported third-quarter net income of $182.944 million, or $0.99 per share, compared with $91.114 million, or $0.50 per share, a year earlier.
M impact | EQUITY | Nov 03, 2026, 09:45 PM UTC
Block shares jump 8.7% after lifting annual profit forecast
Block shares rose 8.7% to $82.4 after the company lifted its annual profit forecast.
M impact | EQUITY | Nov 03, 2026, 09:44 PM UTC